10-Q: Marpai Faces Going Concern Doubt Amid Revenue Plunge

Marpai, Inc. reported a significant revenue decline and continued net losses for Q3 2025, raising substantial doubt about its ability to continue as a going concern, while actively pursuing strategic alternatives and capital raises.

Summary

• Net loss for the nine months ended September 30, 2025, was $10.9 million, an improvement from $20.9 million in the prior year, largely due to the absence of a $7.6 million goodwill impairment charge incurred in 2024.
• Revenue decreased by 34.6% to $14.1 million for the nine months ended September 30, 2025, from $21.6 million in the same period last year, primarily due to customer turnover.
• The company has an accumulated deficit of $109.8 million and negative working capital of $10.7 million as of September 30, 2025.
• Unrestricted cash and cash equivalents stood at $445 thousand as of September 30, 2025.
• Management has determined that the company's liquidity condition raises substantial doubt about its ability to continue as a going concern for the next twelve months.
• The Board is exploring strategic alternatives, including strategic investment, business combination, or sale of the company, to maximize shareholder value.
• Net cash used in operating activities significantly improved to $2.7 million for the nine months ended September 30, 2025, compared to $10.5 million in the prior year.
• The company is involved in a civil complaint for breach of contract, with the plaintiff's expert estimating damages in excess of $5 million.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues, a going concern doubt, significant revenue decline, and ongoing losses. While cost reductions and the absence of a prior-year impairment charge improved the net loss, the underlying business performance and financial health remain highly concerning. The reliance on repeated capital raises, including from insiders, highlights the precarious financial position.

Positives

• Net loss significantly reduced to $10.9 million for the nine months ended September 30, 2025, from $20.9 million in the prior year, partly due to cost streamlining and the absence of a prior year impairment charge.
• Operating loss improved by 55.5% to $8.6 million for the nine months ended September 30, 2025, from $19.4 million in the prior year.
• Net cash used in operating activities decreased substantially to $2.7 million for the nine months ended September 30, 2025, from $10.5 million in the prior year.
• General and administrative expenses decreased by $3.2 million (31.4%) for the nine months ended September 30, 2025, due to streamlining TPA operations.
• Sales and marketing expenses decreased by $532 thousand (38.5%) for the nine months ended September 30, 2025, due to headcount reduction and department consolidation.
• Facilities expenses decreased by $755 thousand (63.1%) for the nine months ended September 30, 2025, due to strategic decommissioning of unutilized facilities.

Negatives

• Revenue decreased by 34.6% to $14.1 million for the nine months ended September 30, 2025, primarily due to customer turnover.
• The company has an accumulated deficit of $109.8 million and negative working capital of $10.7 million as of September 30, 2025.
• Unrestricted cash and cash equivalents are critically low at $445 thousand as of September 30, 2025.
• Management has identified substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• Interest expense increased by 28.6% to $2.4 million for the nine months ended September 30, 2025, primarily due to the JGB debt.
• The company is facing a civil complaint for breach of contract with estimated damages exceeding $5 million.

Risks

• Substantial doubt about the ability to continue as a going concern due to liquidity condition, accumulated deficit, negative working capital, and ongoing net losses.
• Significant revenue decline due to customer turnover, indicating challenges in customer retention and market adaptation.
• Dependence on a few major customers for accounts receivable (two customers accounted for 17.4% and 13.8% of accounts receivable as of September 30, 2025).
• Uncertainty regarding the success of identifying or completing any strategic transaction, which may be costly, time-consuming, and disruptive.
• Potential for significant dilution to existing stockholders from future equity or debt transactions required to fund operations.
• Risk of being forced to scale back operations or divest assets if unable to raise additional capital.
• Exposure to litigation, as evidenced by the ongoing civil complaint with estimated damages over $5 million.
• Impact of global macroeconomic environment, including inflationary pressures, supply chain disruptions, social/political issues, regulatory matters, and geopolitical tensions.
• Foreign exchange risk due to operations in Israel, though currently deemed not material.

Future Outlook

Management projects the need for additional capital to fund current operations and capital investment requirements until the company scales to a revenue level that permits cash self-sufficiency. The Board is actively exploring strategic alternatives, including strategic investments, business combinations (merger), or a sale of the company, to maximize shareholder value. The company is also evaluating the impact of new accounting pronouncements and the 'One Big Beautiful Bill Act' on its financial statements.

Management Comments

• We have combined these two businesses to create what it believes to be the Payer of the Future, which has not only the licenses, processes and know-how of a payer but also the latest technology. This combination allows us to differentiate ourselves in the TPA market by delivering a technology-driven service that it believes can lower the overall cost of healthcare while maintaining or improving healthcare outcomes.
• We continue to monitor the effects of the global macroeconomic environment, including increasing inflationary pressures; supply chain disruptions; tariffs levied by the Trump Administration, social and political issues; regulatory matters, geopolitical tensions; and global security issues. We are also mindful of inflationary pressures on our cost base and are monitoring the impact on customer preferences.
• The decline [in revenue] is primarily due to customer turnover. The market is evolving, and we are adapting our approach to better serve our customers needs.
• Based on our current financial condition, our Board of Directors (the Board), supported by our management team, is considering exploring strategic alternatives focused on maximizing shareholder value.
• Management continues to evaluate additional funding alternatives and is seeking to raise additional funds through the issuance of equity or debt securities.
• The Company does not believe the plaintiff's estimated level of damages is accurate and intends to vigorously defend itself in the litigation.

Industry Context

Marpai operates in the highly competitive U.S. healthcare Third-Party Administrator (TPA) market, aiming to differentiate itself through a technology-driven service model designed to lower healthcare costs and improve outcomes for self-insured employers. The company's stated mission to positively change healthcare for clients, members, and providers aligns with broader industry trends towards value-based care and cost containment. However, the significant customer turnover and revenue decline suggest challenges in executing this strategy or retaining market share amidst evolving customer needs and macroeconomic pressures, including inflation.

Corporate Governance

Legal Proceedings

• On January 30, 2025, the company was served with a civil complaint by Messer Financial Group Inc., a sublessee, for breach of contract.
• A mediation session on July 28, 2025, was unsuccessful in resolving the dispute.
• On September 22, 2025, discovery proceedings commenced, and the plaintiff's expert indicated estimated damages in excess of $5 million. The company intends to vigorously defend itself.

Related Party Transactions

• On January 16, 2024, HillCour Investment Fund LLC (controlled by CEO Damien Lamendola), Chairman Yaron Eitan, and Director Robert Pons purchased 1,322,100 common shares in a private placement at $0.9201 per share.
• On March 7, 2024, HillCour purchased 910,000 common shares in a private placement at $1.65 per share.
• On August 28, 2024, HillCour purchased 1,351,351 common shares (out of 2,702,702 total) in a private placement at $0.481 per share.
• On December 5, 2024, Chairman Yaron Eitan, CFO Steve Johnson, and President and COO John Powers purchased 110,619, 5,000, and 10,000 common shares respectively (out of 621,194 total) in a private placement at $1.13 per share.
• On July 17, 2025, HillCour purchased 86,805 common shares (out of 130,208 total) in a private placement at $1.152 per share.
• On July 29, 2025, HillCour purchased 371,470 common shares (out of 603,640 total) in a private placement at $1.0768 per share.
• On September 10, 2025, HillCour purchased 896,903 common shares (out of 1,038,519 total) in a private placement at $1.0592 per share.
• On September 30, 2025, HillCour purchased 147,058 common shares in a private placement at $1.36 per share.
• On November 7, 2025 (subsequent event), the COO and President, the Chairman, and certain directors of the Board purchased 300,000 common shares and warrants to purchase up to 600,000 common shares (out of 3,850,000 shares and 7,700,000 warrants total) in a private placement at $1.00 per share and accompanying warrant.
• The CEO, Damien Lamendola, provided a guarantee for the Libertas Funding agreement through various entities he controls.

Stakeholder Impact

• Shareholders: Significant dilution from repeated private placements, including to insiders. Risk of further dilution from future capital raises. Uncertainty regarding the outcome of strategic alternatives. Potential for adverse impact on share price due to going concern doubt and litigation.
• Employees: Headcount reductions in sales and marketing, and streamlining of TPA operations indicate potential job insecurity or changes. Share-based compensation plans are in place, but the company's financial health could affect their value.
• Customers: Customer turnover is a primary reason for revenue decline, indicating dissatisfaction or competitive pressures. The company is adapting its approach to better serve customer needs.
• Creditors: The company has substantial debt, including convertible debentures and liabilities to AXA. The going concern doubt raises concerns about the company's ability to meet its obligations.
• Suppliers/Vendors: Cost of revenue includes vendor fees, and the company's financial health could impact its ability to pay suppliers.

Next Steps

• Raise additional capital or secure debt funding to support ongoing operations and capital investment requirements.
• Explore strategic alternatives, including a strategic investment, business combination (merger), or a sale of the company.
• Vigorously defend against the civil complaint by Messer Financial Group Inc.
• Evaluate the impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2024-04, ASU 2025-05, ASU 2025-06) on consolidated financial statements.
• Evaluate the impact of the "One Big Beautiful Bill Act" on consolidated financial statements.

Key Dates

Recommendation

Marpai, Inc. is in a highly precarious financial position, explicitly stating 'substantial doubt about its ability to continue as a going concern.' The company faces significant revenue decline, critically low unrestricted cash, negative working capital, and ongoing net losses. While cost-cutting measures have improved the net loss compared to the prior year (which included a large impairment charge), the core business is struggling with customer turnover. The repeated reliance on dilutive private placements, including heavy insider participation, underscores the urgent need for capital. The exploration of strategic alternatives, including a potential sale, indicates a lack of confidence in the current business model's ability to achieve self-sufficiency. An active civil complaint with estimated damages over $5 million adds further financial risk. Given these severe challenges, the stock carries extreme risk, and a strong sell recommendation is warranted for investors.

Keywords

Marpai, MRAI, 10-Q, Quarterly Report, Financial Results, Healthcare TPA, Third Party Administrator, Self-insured Employers, Going Concern, Revenue Decline, Net Loss, Capital Raise, Strategic Alternatives, Liquidity, Corporate Governance, SEC Filing, Financial Reporting, Risk Factors, Convertible Debentures, Private Placement, OTCQX